While ProQR Therapeutics N.V has overperformed by 5.04%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PRQR rose by 184.89%, with highs and lows ranging from $4.62 to $1.18, whereas the simple moving average jumped by 85.89% in the last 200 days.
On October 29, 2024, Raymond James Upgraded ProQR Therapeutics N.V (NASDAQ: PRQR) to Strong Buy. A report published by Chardan Capital Markets on November 08, 2023, Upgraded its rating to ‘Buy’ for PRQR. JMP Securities also Upgraded PRQR shares as ‘Mkt Outperform’, setting a target price of $5 on the company’s shares in a report dated March 30, 2023. Cantor Fitzgerald December 22, 2022d the rating to Overweight on December 22, 2022, and set its price target from $0.80 to $5. Citigroup February 14, 2022d its ‘Buy’ rating to ‘Neutral’ for PRQR, as published in its report on February 14, 2022. Stifel’s report from February 11, 2022 suggests a price prediction of $3 for PRQR shares, giving the stock a ‘Hold’ rating. Raymond James also rated the stock as ‘Mkt Perform’.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analysis of ProQR Therapeutics N.V (PRQR)
Further, the quarter-over-quarter increase in sales is 183.27%, showing a positive trend in the upcoming months.
ProQR Therapeutics N.V’s future performance can be predicted by a variety of well-rounded types of analysis and research, with equity being one of the most crucial ones. The goal here is to ensure that your current return on equity of -67.62% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 2.33, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can be an extremely valuable indicator of volatility, and PRQR is registering an average volume of 1.29M. On a monthly basis, the volatility of the stock is set at 15.21%, whereas on a weekly basis, it is put at 7.97%, with a gain of 9.09% over the past seven days. Furthermore, long-term investors anticipate a median target price of $6.65, showing growth from the present price of $3.96, which can serve as yet another indication of whether PRQR is worth investing in or should be passed over.
How Do You Analyze ProQR Therapeutics N.V Shares?
Besides checking the fundamentals, you should also know how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 35.41%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 17.62% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
PRQR shares are owned by institutional investors to the tune of 17.62% at present.
